Abstract
Alzheimer's disease (AD) is characterized by extracellular deposits of fibrillar β-amyloid (Aβ) in the brain, a fulminant microglial-mediated inflammatory reaction, and neuronal death. The use of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) is associated with a reduced risk of AD, which has been attributed to the cholesterol-lowering actions of these drugs. Statins have been reported recently to have anti-inflammatory actions in addition to their classic lipid-lowering effects. We report that statins robustly inhibited the Aβ-stimulated expression of interleukin-1β and inducible nitric oxide synthase and the production of nitric oxide by microglia and monocytes. Statin treatment also blocked the rac1-dependent activation of NADPH oxidase and superoxide production. The anti-inflammatory actions of the statins were attributable to their ability to reduce the levels of isoprenyl intermediates in the cholesterol biosynthetic pathway. The effect of statins could not be reversed by exogenous cholesterol supplementation, indicating that the anti-inflammatory actions are distinct from their cholesterol-lowering actions. The addition of the isoprenyl precursors, mevalonic acid, and geranylgeranyl pyrophosphate (GGpp) attenuated the statin-mediated downregulation of inflammatory markers. Prevention of protein isoprenylation by the GGpp transferase inhibitor (GGTI-286) or inhibition of Rho-family function with Clostridium difficile Toxin A blocked the inflammatory response similar to the effect of statin treatment. We argue that the statin-mediated decrease in AD risk arises from their pleiotropic actions, effecting a reduction in neuronal Aβ production and microglia-directed inflammation.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative condition that is characterized by extraneuronal deposits of β-amyloid (Aβ) fibrils (fAβ) and intraneuronal accumulations of hyperphosphorylated tau. AD has a significant inflammatory component evidenced by abundant plaque-associated microglia that exhibit a reactive phenotype (Akiyama and McGeer, 1990; Masliah et al., 1991; Peress et al., 1993; Akiyama et al., 2000). The activated microglia release a diverse array of proinflammatory molecules that act to exacerbate the disease process and contribute to neuronal death (Combs et al., 2000, 2001b; Yates et al., 2000).
Epidemiological studies suggest that treatment with cholesterol-lowering statins reduces the risk of developing AD (Jick et al., 2000; Wolozin et al., 2000; Rockwood et al., 2002). Statins reduce plasma cholesterol levels by inhibiting the rate-limiting enzyme in the cholesterol biosynthetic pathway, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which prevents de novo synthesis of cholesterol (Endo, 1992; Tobert, 2003). Statin treatment has been shown to reduce Aβ production both in vitro and in animal models (Fassbender et al., 2001; Petanceska et al., 2002; Parvathy et al., 2004). Recent prospective studies indicate that statin use reduces soluble Aβ levels in the brain and may improve cognitive function (Buxbaum et al., 2002; Simons et al., 2002; Sjogren et al., 2003; Caballero and Nahata, 2004). These effects are thought to result from reduction in amyloidgenic amyloid precursor protein (APP) processing owing to the sensitivity of β and γ secretases to neuronal membrane cholesterol content (Simons et al., 1998; Kojro et al., 2001; Burns and Duff, 2002; Wahrle et al., 2002; Wolozin, 2002; Cordy et al., 2003; Puglielli et al., 2003).
Statins also exhibit robust anti-inflammatory effects (Pahan et al., 1997; Bellosta et al., 1998; Ortego et al., 1999; Grip et al., 2000, 2002; Wong et al., 2001; Delbosc et al., 2002; Youssef et al., 2002; Zelvyte et al., 2002; Nath et al., 2004). Many of the anti-inflammatory actions of statins are postulated to arise from a reduction of isoprenoid intermediates in the cholesterol biosynthetic pathway (Liao and Laufs, 2004). The isoprenoids geranylgeranyl pyrophosphate (GGpp) and farnesyl pyrophosphate (Fpp) are added to the C termini of small G-proteins facilitating specific interactions with cytoplasmic regulators, cellular membranes, and effectors (Zhang and Casey, 1996). The small G-proteins are essential elements in inflammatory signaling cascades, and thus statin blockade of small G-protein lipid modification acts to functionally inhibit these pathways (Liao, 2002).
The ability of statins to reduce AD risk may arise, in part, through inhibition of microglial-induced inflammation. We report the ability of HMG-CoA reductase inhibitors to downregulate the inflammatory response of THP-1 monocytes and BV-2 microglial cells to Aβ by inhibiting the function of Rho-family small G-proteins. Statin-mediated blockade of HMG-CoA conversion to mevalonate decreases the pools of isoprenoids, inhibits the lipid modification of Rho-family members, and prevents small G-protein-mediated activation of downstream proinflammatory signaling pathways. The beneficial effects of statins are likely derived from both reduced neuronal Aβ production and suppression of microglial inflammatory responses.
Materials and Methods
Materials and reagents. Lipopolysaccharide (LPS), Escherichia coli K12, and D31m4 (Re) were purchased from List Biological Laboratories (Campbell, CA). Stock solutions were prepared with sterile distilled water. Aβ peptides (Aβ25-35 and Aβ1-42), purchased from American Peptide Company (Sunnyvale, CA), were dissolved in sterile water at a concentration of 2 mm and then incubated for 5 d at 37°C to induce fibril formation. Simvastatin and lovastatin were obtained from Calbiochem (La Jolla, CA) and prepared following the instructions of the manufacturer. Briefly, the statin was converted to its active form by dissolving it in absolute ethanol followed by the addition of 1N NaOH. This solution was stored at -20°C until use. Immediately before use, the statin solution was neutralized (pH 7.2) with 1N HCl. Geranylgeranyl pyrophosphate triammonium salt and farnesyl pyrophosphate triammonium salt were purchased from Biomol (Plymouth Meeting, PA) and dissolved in 70% ethanol. The GGpp transferase inhibitor (GGTI-286) and the Fpp transferase inhibitor (FTI-277), were purchased from Calbiochem and were reconstituted in DMSO. Clostridium difficile Toxin A was purchased from Calbiochem. Nitroblue tetrazolium chloride (NBT) was purchased from Roche (Basel, Switzerland). Griess Reagent was purchased from Sigma (St. Louis, MO). The Amplex Red Cholesterol Assay kit was purchased from Molecular Probes (Eugene, OR). Antibodies to interleukin-1β (IL-1β) (3ZD), Rac (05-389), inducible nitric oxide synthase (iNOS) (Sc7271), and extracellular signal-regulated kinase 2 (ERK2) (Sc-154) were obtained from the National Cancer Institute Biological Research Branch Preclinical Repository (Bethesda, MD), Upstate Biotechnology (Waltham, MA), and Santa Cruz Biotechnology (Santa Cruz, CA), respectively.
Cell culture. Human THP-1 monocytes from American Type Culture Collection (Manassas, VA) were cultured in RPMI 1640 (Whittaker Bioproducts, Walkersville, MD) at 37°C and 5% CO2. RPMI was supplemented with 10% heat-inactivated fetal bovine serum (FBS) (SH30397.03; Hyclone, Logan, UT), 50 μm 2-mercaptoethanol, and 15 μg/ml gentamycin. The RPMI serum concentration was lowered to 2% at the beginning of the experiments. Mouse BV-2 microglia were maintained in DMEM at 37°C and 5% CO2. The DMEM was supplemented with 10% fetal bovine serum, 50 μm 2-mercaptoethanol, and 15 μg/ml gentamycin.
IL-1β and iNOS Western blots. THP-1 cells (3 × 106 cells) were plated into 24-well plates in a total volume of 500 μl of 2% heat-inactivated FBS-RPMI plus 5 mm HEPES, pH 7.2. Cells were then pretreated with the indicated compounds (simvastatin, lovastatin, GGpp, Fpp, GTI-286, FTI-277, and Toxin A) for either 6 or 18 h. After the pretreatment period, the cells were stimulated with fibrillar Aβ25-35, LPS, fibrillar Aβ25-35 and LPS, or fibrillar Aβ1-42 for 6 or 18 h. Cells were collected and lysed with radioimmunoprecipitation assay (RIPA) buffer (1% Triton X-100, 20 mm Tris, pH 7.5, 100 mm NaCl, 40 mm NaF, 0.2% SDS, 0.5% deoxycholate, 1 mm EDTA, 1 mm EGTA, and 1 mm Na3VO4). Lysates were sonicated for 10 s on ice and cleared by centrifugation (16,000 × g, 15 min, 4°C). Protein concentration was determined by the Bradford method (Bradford, 1976). The samples (50 μg) were separated on 12% SDS-PAGE gels and transferred to polyvinylidene fluoride membranes. After blocking in a 5% milk solution, blots were incubated overnight at 4°C with anti-IL-1β antibodies (1:1000). iNOS blots were blocked in a 5% bovine serum albumin solution and incubated with anti-iNOS antibodies at a dilution of 1:1000. Bands were visualized by incubation of blots with anti-mouse HRP-conjugated secondary antibodies (1:1000; 90 min at room temperature) and visualized by enhanced chemiluminescence (Pierce, Rockford, IL). Blots were stripped by incubation in stripping buffer (62.5 mm Tris, pH 6.8, 100 mm β-mercaptoethanol, and 2% SDS) for 30 min at 50°C. Protein loading was evaluated by reprobing blots with an anti-ERK2 (1:3000) antibody. Band intensities were quantified using a Bio-Rad (Hercules, CA) Versadoc image analysis hardware/software package.
NO assay. BV-2 cells (5 × 105 cells) were plated in 24-well plates in a total volume of 500 μl of 10% FBS-DMEM plus 5 mm HEPES, pH 7.2. Cells were pretreated with simvastatin for 6 h and then stimulated with Aβ25-35 and LPS for 18 h. One hundred microliters of cell medium were collected and assayed for NO levels with the Griess Reagent (Green et al., 1982). The release of NO was determined indirectly by measuring the absorbance at 540 nm. Duplicate measurements were obtained for each sample. The remainder of the sample (∼300 μl) was used for an MTT assay to normalize the Griess values for cell viability and number. Briefly, 30 μl of MTT solution (1:1000 dilution) was mixed with the sample. This mixture was incubated for 2 h at 37°C, 5% CO2. After incubation, the cell medium was removed, and cells were lysed by the addition of 500 μl of DMSO and rocking at room temperature for 10 min in the dark. Two hundred microliters of lysate were transferred to a 96-well plate, and the absorbance at 550 nm was measured.
Reactive oxygen species assay. BV-2 cells (3.5 × 106 cells) were added to 6-well plates in a total volume of 2 ml of 10% FBS-DMEM plus 5 mm HEPES, pH 7.2. Cells were pretreated with various concentrations of simvastatin for 18 h at 37°C, 5% CO2. After the pretreatment period, the cells were removed from the wells by trypsin treatment and collected. Cells were resuspended in serum-free DMEM containing NBT (final concentration, 1 mg/ml). Aβ25-35 plus LPS were added to the cell solution, and the mixture was incubated for 30 min at 37°C, 5% CO2. Cells were collected and lysed using RIPA buffer and brief sonication (10 s). Aliquots of the samples were added to 96-well plates, and NBT reduction was measured by absorbance at 550 nm in triplicate.
Cholesterol measurement. THP-1 cells (5 × 106 cells) were plated into 24-well plates in a total volume of 500 μl of 2% heat-inactivated FBS-RPMI plus 5 mm HEPES, pH 7.2. Cells were treated with increasing concentrations of simvastatin for 24 h. Cholesterol concentrations were determined using a Molecular Probes Amplex Red cholesterol assay kit. Briefly, cells were lysed and incubated with cholesterol esterase, cholesterol oxidase, horseradish peroxidase, and Amplex Red. Under these conditions, all forms of cholesterol contribute to H2O2 production, which subsequently converts Amplex Red to resorufin in the presence of HRP. The amount of cholesterol was determined indirectly by measuring resorufin absorbance at 560 nm.
Western blot quantification and statistical analysis. The density of IL-1β or iNOS Western blot bands was determined using a Bio-Rad Versadoc image analysis system. Band densities were normalized for protein loading by comparison with Erk2 band densities. Two to three experiments were pooled to create graphical representations. Mean values ±SEM were calculated, and statistical differences were determined using a one-way ANOVA. A Tukey-Kramer post test was used to determine p values.
Results
Statins inhibit the production of IL-1β after Aβ exposure
We have shown previously that exposure of primary microglia and THP-1 monocytes to fibrillar β-amyloid peptides resulted in the production and secretion of various proinflammatory cytokines, including IL-1α, IL-1β, IL-6, and tumor necrosis factor α (TNFα), and the production of reactive oxygen species (ROS) and nitrogen species (McDonald et al., 1997; Combs et al., 1999, 2000, 2001a; Bamberger et al., 2003). These studies have demonstrated that microglia and monocytes interact and respond to fibrillar forms of Aβ1-40, Aβ1-42, or Aβ25-35 with similar efficiency. We investigated whether the HMG-CoA reductase inhibitors affected the ability of these cells to mount a proinflammatory response to fibrillar Aβ. We tested the ability of simvastatin to downregulate the production of IL-1β after stimulation with Aβ. THP-1 monocytes were pretreated with increasing concentrations of simvastatin (1-25 μm) for 6 h (Fig. 1A,B) or 18 h (Fig. 1C,D). IL-1β was induced by incubation with Aβ25-35 (50 μm), LPS (1 μg/ml), or both for 18 h (Fig. 1A,B) or 6 h (Fig. 1C,D). Simvastatin treatment attenuated IL-1β expression in a dose-dependent manner (Fig. 1A-D). This effect was not attributable to a general reduction in protein synthesis as demonstrated by the unchanged levels of Erk2. Furthermore, the statins did not affect cellular viability, which was monitored by MTT assays (data not shown). Figure 1, A and B, also illustrates the synergistic effects observed with the combinatorial stimulation with Aβ and LPS. We observed a similar effect with lovastatin, providing evidence that the suppression of IL-1β expression was reflective of the action of this class of drugs (Fig. 1E). We also observed that stimulation of IL-1β production by exposure of the cells to fibrillar Aβ1-42 (as reported previously) can be attenuated by statin pretreatment (Fig. 1F).
Statins attenuate IL-1β induction after Aβ stimulation. A, THP-1 cells (3 × 106/condition) were pretreated with increasing concentration of simvastatin for 6 h. After pretreatment, Aβ25-35 (50 μm), LPS (1 μg/ml), or Aβ25-35 and LPS were added to the cells and incubated for 18 h. Cell lysates were separated by Western blotting and probed with anti-IL-1β antibodies. Blots were stripped and reprobed with anti-Erk2 antibodies to monitor protein loading. B, Quantification of pooled experiments was performed (n = 3; *p < 0.05, **p < 0.001 compared with Aβ25-35 plus LPS). C, THP-1 cells (3 × 106/condition) were pretreated with increasing concentration of simvastatin for 18 h. After pretreatment, Aβ25-35 (60 μm) and LPS (500 ng/ml) were added to the cells and incubated for 6 h. Cell lysates were separated by Western blotting and probed with anti-IL-1β antibodies. Blots were stripped and reprobed with anti-Erk2 antibodies to monitor protein loading. D, Quantification of pooled experiments was performed (n = 2; *p < 0.05 compared with Aβ25-35 plus LPS). E, THP-1 cells (3 × 106/condition) were pretreated with increasing concentration of lovastatin for 18 h. After pretreatment, Aβ25-35 (50 μm) and LPS (500 ng/ml) were added to the cells and incubated for 6 h. Cell lysates were separated by Western blotting and probed with anti-IL-1β antibodies. Blots were stripped and reprobed with anti-Erk2 antibodies to monitor protein loading. F, THP-1 cells (3 × 106/condition) were pretreated with increasing concentration of lovastatin for 18 h. After pretreatment, Aβ1-42 (1 μm) and LPS (500 ng/ml) were added to the cells and incubated for 6 h. Cell lysates were separated by Western blotting and probed with anti-IL-1β antibodies. Blots were stripped and reprobed with anti-Erk2 antibodies to monitor protein loading. Veh, Vehicle.
Simvastatin inhibits the induction and activity of iNOS after Aβ exposure
Microglial activation is accompanied by the induction of iNOS with the subsequent production of nitric oxide (Weldon et al., 1998; Combs et al., 2001b; Giovannini et al., 2002). We tested whether statin treatment could suppress the expression of iNOS. BV-2 microglia were pretreated with increasing concentrations of simvastatin for 6 h followed by an 18 h stimulation with Aβ/LPS. We observed the dose-dependent ability of simvastatin to downregulate the Aβ/LPS-mediated induction of iNOS by >80% (Fig. 2A,B). There was a parallel simvastatin-mediated reduction in NO levels (Fig. 2C).
Statins attenuate iNOS expression and activity after Aβ stimulation. A, BV-2 cells (1 × 106/condition) were pretreated with increasing concentration of simvastatin for 6 h. After pretreatment, Aβ25-35 (50 μm) and LPS (1 μg/ml) were added to the cells and incubated for 18 h. Cell lysates were separated by Western blotting and probed with anti-iNOS antibodies. Blots were stripped and reprobed with anti-Erk2 antibodies to monitor protein loading. B, Quantification of pooled experiments was performed (n = 3; *p < 0.05 compared with Aβ plus LPS). C, BV-2 cells (5 × 105/condition) were pretreated with increasing concentration of simvastatin for 6 h. After pretreatment, Aβ25-35 (50 μm) and LPS (1 μg/ml) were added to the cells and incubated for 18 h. NO production was measured by Griess reagent and normalized by MTT assay (n = 3; *p < 0.01, **p < 0.001 compared with Aβ plus LPS). Veh, Vehicle.
Simvastatin inhibits the production of reactive oxygen species after Aβ exposure
Aβ stimulation of microglia or monocytes leads to the activation of NADPH oxidase and the production of reactive oxygen species, which are ultimately responsible for much of the cellular oxidative damage (McDonald et al., 1997; Bamberger et al., 2003). We tested whether simvastatin could reduce the generation of superoxide radicals elicited by treatment of the cells with Aβ/LPS. BV-2 microglia were pretreated with increasing concentrations of simvastatin for 18 h and then incubated with Aβ/LPS (Fig. 3). Simvastatin treatment dramatically inhibited NADPH oxidase activation and ROS production. The suppression of ROS generation was quite sensitive to simvastatin, because drug concentrations as low as 1 μm were found to inhibit this response.
Statins attenuate reactive oxygen species production after Aβ stimulation. BV-2 cells (3.5 × 106/condition) were pretreated with increasing concentration of simvastatin (1-20 μm) for 18 h. After pretreatment, Aβ25-35 (60 μm) and LPS (500 ng/ml) were added to the cells and incubated for 30 min. Production of ROS was determined by NBT assay (n = 2; *p < 0.001 compared with Aβ plus LPS). Veh, Vehicle.
Blockade of cholesterol biosynthesis by simvastatin does not account for its anti-inflammatory effects
The primary effect of HMG-CoA reductase inhibitors is to block the synthesis of cholesterol, but it also reduces the cellular pools of all the lipid intermediates in the biosynthetic pathway. We wanted to ascertain whether the anti-inflammatory actions of the statins were a consequence of drug-induced reduction of cellular cholesterol levels. Cholesterol levels were measured in THP-1 cells after treatment with simvastatin for 24 h. Under our experimental conditions, cholesterol levels were unchanged after statin treatment (data not shown). These observations were in agreement with published results that indicate cholesterol-free medium must be used to decrease cellular levels of cholesterol with statin treatment (Kojro et al., 2001). To further investigate the role of cholesterol, THP-1 cells were pretreated for 6 h with simvastatin (25 μm) with or without the addition of increasing concentrations of exogenous cholesterol (25-50 μm). After pretreatment, cells were exposed to Aβ/LPS for 18 h. As shown in Figure 4, A and B, cholesterol supplementation did not attenuate the simvastatin-mediated reduction of IL-1β. These results suggested that the anti-inflammatory actions of simvastatin were independent of cellular cholesterol levels.
Mevalonic acid, but not cholesterol, reverses the anti-inflammatory effects of statins. A, C, THP-1 cells (3 × 106/condition) were pretreated with simvastatin (25 μm) and increasing concentrations of cholesterol (A) or mevalonic acid (C) for 6 h. After pretreatment, Aβ25-35 (50 μm) and LPS (1 μg/ml) were added to the cells and incubated for 18 h. Cell lysates were separated by Western blotting and probed with anti-IL-1β antibodies. Blots were stripped and reprobed with anti-Erk2 antibodies to monitor protein loading. B, D, Quantification of pooled experiments was performed for A and C, respectively (B, n = 3; D, n = 2). Veh, Vehicle.
Supplementation with lipid intermediates of the cholesterol biosynthetic pathway attenuates the anti-inflammatory actions of simvastatin
We hypothesized that if other lipid intermediates in this pathway were involved with the anti-inflammatory actions of simvastatin, they could be identified by supplying these molecules exogenously. The direct product of HMG-CoA reductase, mevalonic acid, was added to the cells in the presence of simvastatin for 6 h. The cells were then exposed to Aβ/LPS for 18 h, and IL-1β levels were measured. The addition of mevalonic acid, attenuated the simvastatin, induced reduction of IL-1β (Fig. 4C,D). These results, coupled with the cholesterol data, indicate that the reduction of molecular intermediates downstream of mevalonic acid, but not cholesterol, is responsible for the anti-inflammatory actions of simvastatin.
We investigated the involvement of the cholesterol biosynthetic intermediates GGpp and Fpp in the anti-inflammatory actions of statins. Fpp serves as a branch point in the metabolic pathway. Although it can be converted to squalene and then on to cholesterol, it can also be converted to GGpp. The isoprenoids Fpp and GGpp serve as substrates for lipid modification of various signaling molecules, including many members of the ras superfamily of small G-proteins. These isoprenyl modifications are necessary for proper cellular localization and function (Zhang and Casey, 1996). We hypothesized that the anti-inflammatory actions of statins could be explained by decreasing the pools of Fpp and GGpp, which would subsequently disrupt G-protein function and downstream intracellular signaling cascades.
THP-1 cells were pretreated with simvastatin in the presence or absence of increasing concentrations of GGpp for 6 h. Subsequently, the cells were exposed to Aβ/LPS for 18 h, and IL-1β protein levels were quantified. The addition of GGpp attenuated the decrease in IL-1β levels caused by simvastatin (Fig. 5A,B). Supplementation with Fpp did not significantly reverse the effects of simvastatin (Fig. 5C,D). These experiments provided clear evidence that the anti-inflammatory actions of statins are mediated by downregulation of the lipid intermediates in the cholesterol biosynthetic pathway. Specifically, this suggests that inhibiting isoprenylation of various proteins by decreasing the pools of GGpp is the mechanism by which statins block the inflammatory response.
GGpp, but not Fpp, reverses the anti-inflammatory effects of statins. A, C, THP-1 cells (3 × 106/condition) were pretreated with simvastatin (25 μm) and increasing concentrations of GGpp (A) or Fpp (C) for 6 h. After pretreatment, Aβ25-35 (50 μm) and LPS (1 μg/ml) were added to the cells and incubated for 18 h. Cell lysates were separated by Western blotting and probed with anti-IL-1β antibodies. Blots were stripped and reprobed with anti-Erk2 antibodies to monitor protein loading. B, D, Quantification of pooled experiments was performed for A and C, respectively (B, n = 6; *p < 0.05; **p < 0.01; D, n = 2). Veh, Vehicle.
Inhibition of isoprenylation attenuates the production of IL-1β after Aβ exposure
We wanted to directly test whether statin-mediated downregulation of protein isoprenylation was responsible for the attenuation in the IL-1β response and hypothesized that a direct inhibition of isoprenylation should mimic the effects of simvastatin. The enzymes responsible for the transfer of GGpp and Fpp to various proteins are geranylgeranyl transferase and farnesyl transferase, respectively. We used specific inhibitors of these enzymes, GTI-286 and FTI-277, to test our hypothesis. THP-1 cells were pretreated with increasing concentration of GTI or FTI for 6 h. We then followed our standard protocol for Aβ/LPS exposure and IL-1β protein detection. Inhibition of the geranylgeranyl transferases resulted in a statistically significant, dose-dependent decrease in IL-1β levels (Fig. 6A,B). Treatment with FTI had no effect on the levels of IL-1β, suggesting that geranylgeranylated, but not farnesylated, proteins are involved in the anti-inflammatory actions of statins.
Inhibition of isoprenylation attenuates IL-1β induction after Aβ stimulation. A, THP-1 cells (3 × 106/condition) were pretreated with GTI for 6 h. After pretreatment, Aβ25-35 (50 μm) and LPS (1 μg/ml) were added to the cells and incubated for 18 h. Cell lysates were separated by Western blotting and probed with anti-IL-1β antibodies. Blots were stripped and reprobed with anti-Erk2 antibodies to monitor protein loading. B, Quantification of pooled experiments was performed (n = 2; *p < 0.01 compared with Aβ plus LPS). Veh, Vehicle.
Inhibition of small G-protein function attenuates the production of IL-1β after Aβ exposure
Isoprenylation of small G-proteins is critical for functional interaction with their effectors and subcellular localization. The Rho family of G-proteins, including Rho, Rac, and Cdc42, are primarily isoprenylated by GGpp. Because the inhibition of GGpp transferase mimicked the anti-inflammatory effects of statins, we hypothesized that the anti-inflammatory actions of the statins were a consequence of inhibition of Rho family GTPase function. We investigated the role of the Rho family of G-proteins in Aβ-stimulated IL-1β production by use of a specific inhibitor of this class of GTPases. Clostridium difficile Toxin A ADP-ribosylates G-proteins of the Rho family and renders them inactive. THP-1 cells were pretreated with increasing concentrations of Toxin A for 2 h. The cells were then exposed to Aβ/LPS for 6 h, and IL-1β levels were determined (Fig. 7A). Toxin A treatment greatly reduced the Aβ/LPS-induced production of IL-1β. The reduction in IL-1β was statistically significant at Toxin A concentrations as low as 10 nm (Fig. 7B). These experiments provide strong evidence that the anti-inflammatory effects of statins are derived from their ability to suppress Rho family G-protein function by limiting GGpp levels and subsequently inhibiting isoprenylation.
Inhibition of Rho-family small G-protein function attenuates IL-1β induction after Aβ stimulation. A, THP-1 cells (3 × 106/condition) were pretreated with increasing concentrations of Clostridium difficile Toxin A for 2 h. After pretreatment, the cells were incubated with Aβ25-35 (50 μm) and LPS (1 μg/ml) for an additional 6 h. Cell lysates were separated by Western blotting and probed with anti-IL-1β antibodies. Blots were stripped and reprobed with anti-Erk2 antibodies to monitor protein loading. B, Quantification of pooled experiments was performed (n = 2; *p < 0.05 compared with Aβ plus LPS). Veh, Vehicle.
Discussion
Our interest has focused on the role of inflammation in the AD brain and how the microglial-mediated proinflammatory response serves to exacerbate and drive the pathogenic processes leading to neuronal loss. Indeed, there is a substantial body of data documenting that microglial activation arises as a secondary consequence of the disease process and acts to facilitate amyloid production and deposition in the brain (Akiyama et al., 2000). Microglia are physically associated with Aβ plaques and display a reactive phenotype, which is typified by increased cell surface expression of major histocompatibility complex class II (Rogers et al., 1988), CD11b, CD45, and immunoglobulin receptor FcγRI (Akiyama and McGeer, 1990; McGeer and McGeer, 2003) along with other proinflammatory markers. Furthermore, microglia exposed to Aβ in the AD brain or in vitro release proinflammatory cytokines, including IL-1β, IL-6, and TNFα (Xia et al., 1998; Hesselgesser and Horuk, 1999; Akiyama et al., 2000; Grammas and Ovase, 2002; Haas et al., 2002; Smits et al., 2002). Inflammation acts to augment disease progression via its ability to stimulate neuronal Aβ production (Blasko et al., 2001; Sastre et al., 2003; Sheng et al., 2003) and facilitate amyloid deposition (Qiao et al., 2001; Guo et al., 2002).
The conclusion that statin therapy may be beneficial to AD patients arose from three retrospective studies that demonstrated the positive effects of statins on the risk of developing AD. Wolozin et al. (2000) used a cross-sectional analysis design and reported that the risk of developing AD in patients receiving statin therapy was 60-73% lower than the general population. Subsequent retrospective studies and prospective clinical investigations strengthened this hypothesis (Jick et al., 2000; Rockwood et al., 2002; Caballero and Nahata, 2004).
The salutary effects of these drugs in AD have been interpreted to arise exclusively from their cholesterol-lowering effects. Indeed, there is a strong rationale linking statin use with reduced neuronal synthesis and secretion of amyloidogenic Aβ peptides. The epidemiological findings have found conceptual support in studies of animal models of AD, demonstrating that high-cholesterol diets result in exacerbation of Aβ deposition, an effect that is reversed by statin treatment (Fassbender et al., 2001; Refolo et al., 2001; Petanceska et al., 2002). Recent clinical investigations have demonstrated the ability of statins to modulate neuronal APP processing. Sjogren et al. (2003) observed reduced CSF α- and β-sAPP levels after 12 weeks of simvastatin therapy. Moreover, statin use has been correlated with a reduction in serum and CSF Aβ levels and brain hydroxycholesterol levels (Buxbaum et al., 2002; Simons et al., 2002). It has been argued that the basis of these effects is the dependence of APP processing on neuronal membrane cholesterol content. In vitro experiments have shown that statin treatment and changes in cellular cholesterol levels can modulate Aβ homeostasis (Burns and Duff, 2002). The activities of all three secretases involved in APP processing are acutely sensitive to cholesterol levels (Bodovitz and Klein, 1996; Simons et al., 1998; Wahrle et al., 2002). Depletion of cholesterol from cellular membranes decreases the activities of β- and γ-secretases, whereas cholesterol supplementation can inhibit α-secretase activity (Burns and Duff, 2002). It has been argued that reduction in membrane cholesterol would shunt APP processing into the α-secretase pathway by decreasing the activity of the amyloidogenic secretases.
It has only recently been appreciated that HMG-CoA reductase inhibitors have anti-inflammatory effects that are independent of their ability to lower cholesterol levels. These observations were initially described by cardiovascular biologists who observed that statin-mediated protection from vascular accidents did not correlate with cholesterol reduction (Takemoto and Liao, 2001). Statin treatment has been shown to reduce levels of matrix metalloproteinase-9, TNF-α, and monocyte chemotactic protein-1 (Bellosta et al., 1998; Grip et al., 2000, 2002; Wong et al., 2001) and decrease the activities of NF-kB, the NADPH oxidase complex, and iNOS (Pahan et al., 1997; Ortego et al., 1999; Delbosc et al., 2002; Zelvyte et al., 2002) in both vascular and myeloid-lineage cells. The efficacy of this class of drugs as anti-inflammatory agents in the CNS has been convincingly demonstrated in a murine model of experimental allergic encephalitis (Youssef et al., 2002; Nath et al., 2004). Statins have also been shown to protect neurons from excitotoxic injury (Zacco et al., 2003).
In the present study, we have shown that Aβ/LPS stimulation results in the production of a number of inflammatory markers, including IL-1β, iNOS, and reactive nitrogen and oxygen species. Importantly, statin treatment attenuates these Aβ-mediated proinflammatory responses. The statin-mediated suppression of inflammation is independent of cholesterol reduction but dependent on proximal elements of the cholesterol biosynthetic pathway required for GGpp-mediated isoprenylation of Rho family members. The anti-inflammatory actions of the statins arise from lower levels of functionally active, lipid-modified members of the Rho family of small G-proteins, which are critical regulators of inflammatory signaling pathways. The isoprenyl group is transferred to the C terminus of the G-protein, and this modification is required for transfer and localization to the plasma membrane (Zhang and Casey, 1996). The lipid moiety intercalates into the membrane, allowing stable localization of the protein at the inner face of the membrane and access to its downstream effectors. Isoprenylation is also required for retention of Rac and Rho in the cytoplasm in resting cells through the interaction of the lipid moiety with Rho-GDP dissociation inhibitor (GDI), which serves as a cytoplasmic anchor for the G-proteins. After stimulation, Rho-GDI participates in the ligand-stimulated translocation of the G-protein to the membrane and facilitates its conversion into an active conformation. Inhibition of protein isoprenylation or block of Rho family G-protein action resulted in inhibition of inflammatory gene expression in a manner identical to that of the statins.
The observation that statins may significantly reduce AD risk has been interpreted previously to be exclusively the result of their cholesterol-lowering actions. The secretases involved with APP processing are sensitive to membrane cholesterol levels, and it was thought disease protection could be explained by their ability to prevent Aβ production. One of the principal conclusions of the present study is that statins exert potent anti-inflammatory effects, which adds a new dimension to the actions of statins in the AD brain. There is a strong rationale for why anti-inflammatory therapies may be efficacious in the treatment of AD. We argue that the clinical efficacy of these drugs is attributable to their pleiotropic actions, acting in a cholesterol-dependent manner to suppress neuronal Aβ synthesis and in a cholesterol-independent manner to inhibit microglial proinflammatory reactions.
The recognition that the statins may have multiple independent actions on AD pathophysiology parallels the recent observations regarding the mechanisms of action of NSAIDs in the disease. Epidemiological studies have demonstrated that chronic use of NSAIDs, like the statins, reduces the risk of developing AD by ∼70% (Etminan et al., 2003). Recent observations of the pleiotropic actions of NSAIDs have forced a substantial reevaluation of how these drugs act to affect AD. NSAIDs, traditionally administered to attenuate inflammatory reactions, have been shown to suppress microglia-mediated inflammation and subsequent neuronal death. Indeed, ibuprofen treatment suppresses microglial activation in animal models of AD (Lim et al., 2000; Yan et al., 2003) and reduces the number of plaque-associated microglia in the AD brain (Mackenzie and Munoz, 1998). Importantly, it has recently been reported that a subset of NSAIDs inhibits the synthesis of the amyloidgenic Aβ1-42 by direct interaction with the γ-secretase (Weggen et al., 2001, 2003) or by inhibiting RhoA-dependent signaling events (Zhou et al., 2003). Together, these findings suggest that both classes of drugs exhibit pleiotropic actions that may underlie their efficacy in reducing AD risk. Statins and NSAIDs share a common general mechanism to alter AD pathogenesis in which APP processing is downregulated in neurons and inflammatory responses are suppressed in microglia. The effects of statin therapy on AD risk and progression are now being evaluated in large-scale clinical trials. The present study offers a more complex view of the mechanism of action of these drugs.
Footnotes
This work was supported by National Institutes of Health Grant AG 16704 and in part by Case Western Reserve University Medical Scientist Training Program Grant T32 GM07250. We thank the Blanchett Rockefeller Foundation and the Coins for Alzheimer's Research Trust Fund of Rotary International for generous support of our work.
Correspondence should be addressed to Gary Landreth, Alzheimer Research Laboratory, E504, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106. E-mail: gel2{at}cwru.edu.
Copyright © 2005 Society for Neuroscience 0270-6474/05/250299-09$15.00/0
References
In this issue
